|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients
| Title: | Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients |
| Authors: | Naya, Masanao Browse this author | | Tsukamoto, Takahiro Browse this author | | Morita, Koichi Browse this author | | Katoh, Chietsugu Browse this author | | Furumoto, Tomoo Browse this author | | Fujii, Satoshi Browse this author | | Tamaki, Nagara Browse this author | | Tsutsui, Hiroyuki Browse this author →KAKEN DB |
| Keywords: | coronary endothelial function | | olmesartan | | amlodipine | | hypertension | | positron emission tomography |
| Issue Date: | 18-Sep-2007 |
| Publisher: | Elsevier Inc. |
| Journal Title: | Journal of the American College of Cardiology |
| Volume: | 50 |
| Issue: | 12 |
| Start Page: | 1144 |
| End Page: | 1149 |
| Publisher DOI: | 10.1016/j.jacc.2007.06.013 |
| PMID: | 17868805 |
| Abstract: | Objectives: We aimed to compare the effects of angiotensin II receptor blocker (ARB) olmesartan versus calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension.
Background: ARB is thought to have greater beneficial effects on coronary vasomotion via directly blocking action of angiotensin II than CCB.
Methods: Twenty-sex patients with untreated essential hypertension were prospectively assigned to the treatment with either olmesartan (27.7±12.4 mg per day, n=13) or amlodipine (5.6±1.5 mg per day, n=13) for 12 weeks. Changes of corrected myocardial blood flow (ΔMBF) and coronary vascular resistance (ΔCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, hs-CRP, interleukin-6, tumor necrosis factor-α, and superoxide dismutase (SOD) were also measured.
Results: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (−28.7±16.2 vs. −26.7±10.8 mmHg). In olmesartan group, ΔMBF tended to be greater (−0.15±0.19 vs. 0.03±0.17 ml/g/min, P=0.09 by 2-way ANOVA) and ΔCVR was significantly decreased (7.9±23.5 vs. −16.6±18.0 mmHg/[ml/g/min], P<0.05) after treatment whereas they did not change in amlodipine group (ΔMBF: −0.15±0.12 vs. −0.12±0.20 ml/g/min; ΔCVR: 6.5±18.2 vs. 4.8±23.4 mmHg/[ml/g/min]). Serum SOD activity tended to increase (4.74±4.77 vs. 5.57±4.74 U/ml, P=0.07 by 2-way ANOVA) only in olmesartan group.
Conclusions: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independently of BP lowering. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs. |
| Relation: | http://content.onlinejacc.org/ |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/30255 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 納谷 昌直
|
